{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:56:36Z","timestamp":1794408996565,"version":"4.9.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:00:00Z","timestamp":1791676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Government of Japan Ministry of Health Labour and Welfare","doi-asserted-by":"publisher","award":["23FC1009"],"award-info":[{"award-number":["23FC1009"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jns.2026.126212","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:47:28Z","timestamp":1791672448000},"page":"126212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A potential biomarker for the efficacy of complement inhibitors in myasthenia gravis"],"prefix":"10.1016","volume":"491","author":[{"given":"Etsuko","family":"Ogaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Akamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manato","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kurumada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyosuke","family":"Takasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2026.126212_bb0005","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2026.126212_bb0010","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/eci.12.34","article-title":"Muscle autoantibodies in myasthenia gravis: beyond diagnosis?","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.jns.2026.126212_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2203","article-title":"No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: a systematic retrospective study involving 67 patients","volume":"11","author":"Wang","year":"2021","journal-title":"Brain Behav."},{"key":"10.1016\/j.jns.2026.126212_bb0020","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/jnnp-2020-325511","article-title":"Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome","volume":"92","author":"Kojima","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2026.126212_bb0025","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mus.23944","article-title":"Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?","volume":"49","author":"Sanders","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2026.126212_bb0030","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179742","article-title":"Myasthenia gravis: the future is here","volume":"134","author":"Kaminski","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jns.2026.126212_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00917","article-title":"Complement inhibitor therapy for myasthenia gravis","volume":"11","author":"Albazli","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2026.126212_bb0040","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16490","article-title":"Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis","volume":"31","author":"Habib","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2026.126212_bb0045","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2026.126212_bb0050","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/acn3.51376","article-title":"Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses","volume":"8","author":"Howard","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jns.2026.126212_bb0055","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1172\/JCI122942","article-title":"Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica","volume":"129","author":"Soltys","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jns.2026.126212_bb0060","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/acn3.51761","article-title":"Clinicoserological insights into patients with immune checkpoint inhibitor-induced myasthenia gravis","volume":"10","author":"Masi","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jns.2026.126212_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105231","article-title":"Identification of disease phenotypes in acetylcholine receptor-antibody myasthenia gravis using proteomics-based consensus clustering","volume":"105","author":"Nelke","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jns.2026.126212_bb0070","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001169","article-title":"Heterogeneity of acetylcholine receptor autoantibody-mediated complement activity in patients with myasthenia gravis","volume":"9","author":"Obaid","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jns.2026.126212_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10061360","article-title":"Complement activation profile in myasthenia gravis patients: perspectives for tailoring anti-complement therapy","volume":"10","author":"Iacomino","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.jns.2026.126212_bb0080","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/mus.21398","article-title":"Correlation of C3 level with severity of generalized myasthenia gravis","volume":"40","author":"Liu","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2026.126212_bb0085","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/ene.14500","article-title":"Changes in serum complements and their regulators in generalized myasthenia gravis","volume":"28","author":"Ozawa","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2026.126212_bb0090","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/ene.15730","article-title":"Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis","volume":"30","author":"Stascheit","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2026.126212_bb0095","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1212\/WNL.27.4.307","article-title":"Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model","volume":"27","author":"Engel","year":"1977","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.126212_bb0100","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF00697195","article-title":"Induction of the morphologic changes of both acute and chronic experimental myasthenia by monoclonal antibody directed against acetylcholine receptor","volume":"63","author":"Gomez","year":"1984","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jns.2026.126212_bb0105","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200436","article-title":"AChR autoantibody pathogenic properties are heterogeneously distributed and undergo temporal changes among patients with myasthenia gravis","volume":"12","author":"Khani-Habibabadi","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26004946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26004946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:57:28Z","timestamp":1791939448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26004946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":21,"alternative-id":["S0022510X26004946"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.126212","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A potential biomarker for the efficacy of complement inhibitors in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.126212","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"126212"}}